Regeneron Pharmaceuticals, Inc.

Nicolin Bloch

Samuel H Davis

Tong Zhang

Jiaxi Wu

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R&#x3b1;. The IL-2 variants may retain the ability in binding to or activating IL-2R&#x3b2; and/or IL-2R&#x3b2;&#x3b3;. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Growing community of inventors

Ossining, NY, United States of America

Nicolin Bloch